InnoCare Pharma and KeyMed Biosciences have announced an exclusive partnership with Prolium Bioscience to develop and commercialise ICP-B02 (CM355), a promising CD20xCD3 bispecific antibody. This agreement covers the non-oncology field globally and the oncology field in regions outside of Asia.
Micron Biomedical, based in Atlanta, has secured additional funding to further its mission of simplifying drug and vaccine delivery. The Series A funding round, now totalling $33 million, was co-led by J2 Ventures and the Global Health Investment Corporation (GHIC).
Kincell Bio, a cell therapy development and manufacturing organisation, has announced the appointment of Mark R. Bamforth as Chief Executive Officer (CEO). Effective immediately, Bamforth brings decades of experience in the biopharmaceutical industry to the role, having founded and led
Diverchim, a renowned French Contract Development and Manufacturing Organization (CDMO), has announced the acquisition of Innoverda, a Contract Research Organization (CRO) known for its electrochemical process solutions. The deal merges Diverchim’s strengths in drug substance development with Innoverda’s expertise in
Manufacturing strategy has become a critical differentiator in biotech funding rounds, directly impacting company valuation and exit opportunities. This guide helps biotech leaders prepare for investor scrutiny of their manufacturing approach, ensuring your strategy demonstrates both operational maturity and commercial
Be Bio, has successfully closed a $92 million Series C financing round. The funding was backed by new investor Nextech, along with existing investors such as ARCH Venture Partners, Atlas Venture, RA Capital Management, Alta Partners, Longwood Fund, Bristol Myers
Granata Bio Corporation, a biopharma company addressing the global infertility medication market valued at $3.6 billion, has successfully closed a $15 million Series A+ funding round. This round was exclusively backed by existing investors, including Gedeon Richter, CooperSurgical, Amboy Street
Tanvex BioPharma, Inc. has announced the completion of its acquisition of Bora Biologics Co., Ltd., a subsidiary of Bora Pharmaceuticals. The combined entity’s CDMO services will operate under the Bora Biologics name while continuing to be owned by Tanvex. “The
Tune Therapeutics, a leading epigenome editing company, has secured over $175 million in financing to further the development of its innovative therapies targeting chronic and common diseases. The funding round was led by prominent investors including New Enterprise Associates, Yosemite,
Immunis, Inc., a clinical-stage biotechnology company focused on developing multi-active biologics for immune-related diseases, has raised $25 million in its Series A-1 financing round. This funding will be used to support two Phase 2 clinical trials for IMM01-STEM, a promising
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
